Sign in
CompletedPhase 2

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Key facts

Who runs it
Zhejiang University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
227 people enrolled
Started
1 Jun 2025
Ended
2 Jun 2026
Type of study
Interventional
Treatments tested
  • oxytocin nasal spray
Record updated
20 August 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Age ≥ 65 years
  • Patients who were to undergo elective orthopedic surgery under general anesthesia with tracheal intubation
  • ASA class I-III
  • Estimated duration of surgery ≥ 1 hour; (5) The patient himself/herself or his/her legal representative
  • Informed consent from the patient or legal representative
  • Proficiency in the use of Chinese language for communication

Who cannot take part

  • Patients with previous psychiatric and neurological disorders, such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease; Goldson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, and so on
  • Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery
  • Patients who are scheduled for 2 surgeries within 7 days of surgery
  • Oxytocin allergy
  • Patients with severe hepatic insufficiency (Child-Pugh class C)
  • patients with severe renal insufficiency (dialysis is required before surgery)
  • Severe heart failure (METS<4)
  • Preoperative inability to communicate (coma or dementia)
  • Patients with bone malignancy
  • Nasal cavity occupation, patients with fillers in the nose
  • Pregnant and lactating women
  • Severe preoperative blindness, deafness, or inability to understand Mandarin to complete preoperative delirium screening
  • Currently participating in other clinical trials

Other criteria

  • Elderly patients undergoing orthopedic surgery under general anesthesia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postoperative delirium is a delirium that occurs within 7 days after surgery or before hospital discharge. It has been shown that combined POD can increase the incidence of postoperative pulmonary infections, deep vein thrombosis and decubitus ulcers, and increase the incidence of disability and mortality. The incidence of postoperative delirium in geriatric orthopedics is high.

Read full original descriptionShow less

Investigators conduct a prospective clinical study on geriatric orthopedic surgery patients to investigate the effect of oxytocin nasal spray on the prevention of postoperative delirium in geriatric orthopedic surgery. Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia. Before the end of surgery, the Investigators administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and in the evening. Until 7 days after surgery or discharge. The sample size are 77 cases in phase I and 143 cases in phase 2, total 220 cases.

The group in the trial

  • Oxytocin nasal spray given to geriatric orthopedic general anesthesia patientsTreatment being tested

    Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia.Before the end of anesthesia, the experimenter administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and 24 IU in the evening.Until 7 days after surgery or discharge.

    Treatment: oxytocin nasal spray

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery:Two-Stage Designs for Phase II Clinical Trials
Record updated
20 August 2026